Start with Episode 1 here:

Some immune cells in Long COVID patients never got the order to stand down. This episode breaks down T cell exhaustion, a real, measurable state where killer T cells stay present in the body but lose their firepower after fighting an infection for too long.

We explain what a killer T…

Read more

Marcus started the iron supplement under his doctor’s advice three months ago. His energy came back first, then his color. The follow-up blood work looked good: hemoglobin up, ferritin climbing. His doctor was pleased. Marcus was pleased. Case closed.

Except it wasn’t. Nobody had asked why a man in his 60s, eating normally, with no history of anemia, had suddenly gone low on iron. The daily ibuprofen he’d been taking for his knee for years never came up. Neither did a colonoscopy.

This article explores why simply taking a supplement is often not enough, and what additional investigations should have been considered. The problem gets addressed here, not because Marcus’s story is rare, but because it’s common enough to be the main lesson.

The number was never the danger

Iron deficiency can be a warning sign for a problem you can’t see or feel. In adult men and women past menopause, doctors always look for hidden bleeding if there isn’t an obvious reason for low iron. Taking a supplement might make your lab results look better, but it doesn’t fix the cause if something bigger is going on.

Colorectal cancer is the case that shows up most in the research, and for a specific reason. Right-sided tumors, the ones tucked further up the colon, tend to bleed slowly and quietly rather than producing visible blood in the stool. That slow trickle drains iron for months before anything else announces itself. In one large UK study, iron-deficiency anemia was the strongest predictor of exactly that kind of tumor. And the deficiency-first patients weren’t diagnosed later or diagnosed more severely. They were caught earlier. The number that everyone wanted to just “treat” was actually the earliest warning the disease gave.

Celiac disease runs the same playbook from a different direction. It can cause years of quiet intestinal damage with no digestive symptoms at all. In people who show up with unexplained iron deficiency and nothing else, a real slice of them turn out to have celiac disease sitting underneath it. No stomach pain. No diarrhea. Just tired, and low on iron, until someone finally asks why.

Finding out you’re low is the beginning of the question, not the end of it.

Why even a good search doesn’t ask this for you

If you’ve ever typed your symptoms into a search engine or an AI tool, you already know what happens. You get diet advice first, maybe a supplement recommendation, occasionally a mention of heavy periods. The serious causes are in there somewhere, but they’re usually buried behind a follow-up question you didn’t know to ask. Nobody volunteers “have you considered we should rule out cancer” unprompted, and reasonably so. It’s why a structured map matters more than a good guess. You shouldn’t have to know the right question to get the right answer.

The rule-out map

Not every cause of iron deficiency is equally serious, and treating them all the same is how the dangerous ones get missed. Here’s a way to think about it: this map is sorted by how bad it would be to miss a cause, not by how often it happens.

Read more

Read more

Why “eat more steak” addresses only one way the body can run short of iron.

Over the last few articles, we’ve gotten to know the early hints that something might be off with iron. The last article, especially, laid out some of those clues: tiredness that sleep can’t fix, cold hands, a heart that pounds on the stairs, and odd cravings for ice or even a fingernail that starts curving strangely. These symptoms can wave a flag that something’s wrong, and sometimes even whisper that iron is the culprit.

But they cannot reveal why the iron is low.

Throughout this whole series, understanding why iron is low will remain a top priority. This is where many people, and even clinicians, take a wrong turn: the usual recommendation is to supplement more iron or eat extra steak, and then move on. My focus is not on a supplement or a steak, but on understanding the root cause of the deficiency, which, in itself, can be a biomarker for many other diseases. So over the next few articles, we will start to understand which other tests you should get and the meaningful discussions you should have with your doctor to identify the root cause of iron deficiency and maybe prevent a disease before it manifests.

Previously, we talked about four doors that lead to iron deficiency. But there is a fifth, and this door can look just like the others and trick the tests doctors usually perform to understand the deficiency. We are going to address all of them. Only the first one, not getting enough iron, is the problem a steak or a supplement can solve. This is why advice to supplement with iron can bring one person back to health but not help the next. They are arriving at the same place, but the deficiencies are taking different roads to get there.

So picture in your mind a room with four doors. Iron balance is the room, and there are four doors people with iron shortages can enter. A body can run low for different reasons, such as

1. Maybe there just isn’t enough iron in the food to begin with

2. Maybe iron is making it in, but the body can’t grab hold of it.

3. Maybe because it is leaking out somewhere

4. Sometimes, the body simply needs more than usual, and supply can’t keep up.

These are the four doors: intake, absorption, loss, and demand.

As we move forward, we will first sort every cause of iron deficiency into those four, and start to really understand how iron deficiency works. Then we will deal with the impostor, the fifth door.

Door 1: Not enough coming in

This is the door everyone thinks they came through, because it is the only door people talk about, and clinicians focus on. Sometimes that assumption is not wrong. Iron deficiency really sneaks up on you with simple lifestyle changes. Various dietary changes can genuinely lead to an iron deficiency. Reducing the amount of red meat, changing to a vegetarian lifestyle, not accounting for the fact that plant iron is harder to absorb, calorie restriction, or even using modern GLP-1 weight-loss medications that quietly lower your food intake across the board.

There are two different approaches to this door, one that is obvious and another that’s sneaky. The obvious version is simple: the diet just doesn’t supply enough iron.

Read more

That’s the theory behind a surgery now spreading across hospitals in China. Some patients with severe Alzheimer’s have shown dramatic improvement within days.

Here’s what’s actually happening.

Surgeons connect tiny lymphatic vessels in the neck to nearby veins, creating a new exit route for fluid leaving the brain. It’s called deep cervical lymphatic-venous anastomosis (dcLVA).

It started with one surgeon in Hangzhou in 2022. By 2023, viral patient videos had hospitals across China racing to offer it. Thousands of patients have now had it done, some paying over $30,000.

Chinese regulators have since restricted it to formal research settings.

The largest study so far followed 139 patients with severe Alzheimer’s and reported improvements in cognitive scores and Alzheimer’s-related proteins over 6 months.

But we still don’t know if the surgery caused those changes, or how long they last.

There’s a real excitement around p-tau217 right now, and I am too. Biomarkers and blood-based tests like this are a breakthrough for Alzheimer’s research because now we can detect risk of Alzheimer’s 10 years before disease symptoms hit.

But here’s my concern. p-tau217 is a single biomarker.

Alzheimer’s disease is not just one disease; it’s many. In other words, Alzheimer’s disease has subtypes, and these subtypes might need specific treatment options.

Relying on one biomarker means we can risk missing these subtypes and overlook treatment options for a patient.

AAIC 2026

This was highlighted in the recent AAIC 2026 conference where scientists agreed that p-tau217 alone “cannot fully predict an individual’s future risk.”

This is an important conversation because age, genetics, environment, gender, gut microbiome, kidney function, obesity, and underlying conditions all can be risk factors for Alzheimer’s

and can change how a person could develop Alzheimer’s. One biomarker alone will not identify the root causes of Alzheimer’s, which are required for proper treatment.

Biomarker panel

We can get a full picture with a biomarker panel, which should be available in labs.

p-tau217, GFAP, NfL, p-tau181, amyloid (Aβ42/40) panel run together can give a broader understanding of the risk

p-tau217 is the signal that shows the buildup of tau tangles, which is the hallmark of Alzheimer’s disease.

GFAP is a neuroinflammation marker

NfL is a marker that signals when brain cells are being damaged

Amyloid (Aβ42/40) signals plaque development in the brain, which is another hallmark of Alzheimer’s disease.

p-tau181 is an earlier tau marker, not as precise as p-tau217, but can be valuable for diagnosis when in a panel.

Talk to your doctor about the availability of these biomarkers. Amyloid (Aβ42/40) and p-tau217 (Lumipulse test) are FDA-approved, and your insurance might (not guaranteed) cover the cost. But it’s worth talking to your medical provider about the actual cost to you.

Let’s look at an example with a made-up scenario.

Patient A tests using a biomarker panel and his/her result is

High p-tau217 - This shows that the patient is at risk for Alzheimer’s

High GFAP - This shows that the person has neuroinflammation, which can be the main driver of the disease

Low NfL - This shows that the brain damage marker is low.

Patient B tests using a biomarker panel and his/her result is

High p-tau217 - This shows that the patient is at risk for Alzheimer’s

Low GFAP - This shows that the person has low neuroinflammation

High NfL - This shows that the brain damage marker is high and possibly could be the main driver of the disease.

They both tested for p-tau217, but the underlying root causes that could be driving their disease could be different. These root causes could decide which treatment package for each patient.

Other Biomarkers

I recently talked about a study that focused on Circular RNA (circRNA).

In this study, circRNA alone (AUC 0.945) outperformed p-tau217 alone (AUC 0.877).

When the researchers combined circRNA with p-tau217, the accuracy improved over just one biomarker alone (AUC 0.977)

This accuracy was almost as close to the traditional CSF/PET scan imaging used for Alzheimer’s disease risk prediction, but without the invasive side attached to it.

This is the reason why I have been advocating for multiple biomarkers for a more accurate and better diagnosis of Alzheimer’s risk. Plus, it can also help us understand root causes and what is driving the disease.

Alzheimer’s is not one disease. It is not one size fits all.

One biomarker test is not enough.

There will not be one universal cure

Sporadic Alzheimer’s does not start the day a person’s symptoms appear. It starts 10-20 years before symptoms develop and gradually progresses. This timeline is called the prodromal period, where different risk factors work together to increase the chance of developing Alzheimer’s disease. Catching the disease risk around this timeline will help a patient understand what risk factors drive the disease and thereby allow doctors to address the risk factors to hopefully prevent or at least delay the onset of disease symptoms.

The discovery of risk factors and biomarkers that underlie this devastating disease has been a breakthrough. Recently, the FDA cleared a blood test called Lumipulse that detects p-tau217 and amyloid, two hallmarks of Alzheimer’s disease.

The biomarker that got everyone excited: p-tau217

There’s a real excitement around p-tau217 right now, and I am too. Biomarkers and blood-based tests like this are a breakthrough for Alzheimer’s research. Studies show that p-tau217 can detect risk of Alzheimer’s disease at least 10 years before disease symptoms hit, with 90% accuracy.

When everyone was celebrating, I had some concerns about using p-tau217 as a single biomarker. And that brings the conversation to my favorite phrasing. “Alzheimers disease is not one size fits all.”

Alzheimer’s disease is not just one disease; it’s many. In other words, Alzheimer’s disease has subtypes, and these subtypes might need specific treatment options. Relying on one biomarker means we can risk missing these subtypes and overlook treatment options for a patient.

AAIC 2026

Recently, I was listening to some talks at the Alzheimer’s Association International Conference (AAIC), and one discussion really got me excited. For the first time, I heard scientists openly agree: “p-tau217 alone cannot fully predict an individual’s future risk.”

This is an important conversation because age, genetics, environment, gender, gut microbiome, kidney function, obesity, and underlying conditions all can be risk factors for Alzheimer’s disease. All these factors can change how a person could develop Alzheimer’s. That means there are different subtypes of the disease, each with its own disease driver or drivers. Relying on one biomarker is not enough to identify the root causes or disease progression of different Alzheimer’s subtypes. Identification of correct subtypes is required for proper treatment.

Biomarker panels I have used

We can get a full picture with a biomarker panel, which should be available in labs. In my studies, I have used p-tau217, GFAP, NfL, p-tau181, and amyloid (Aβ42/40) as a panel; running them together can give a broader understanding of the risk. Let’s look at what these biomarkers signify.

• p-tau217 is the signal that shows the buildup of tau tangles, which is the hallmark of Alzheimer’s disease.

• GFAP is a neuroinflammation marker

• NfL is a marker that signals when brain cells are being damaged.

• Amyloid (Aβ42/40) signals plaque development in the brain, which is another hallmark of Alzheimer’s disease.

• p-tau181 is an earlier tau marker, not as precise as p-tau217, but can be valuable for diagnosis when in a panel.

Talk to your doctor about the availability of these biomarkers. Amyloid (Aβ42/40) and p-tau217 (Lumipulse test) are FDA-cleared, and your insurance might (not guaranteed) cover the cost. But it’s worth talking to your medical provider about the actual cost to you.

Let’s look at an example with a made-up scenario.

Two patients walk in to get tested for Alzheimer’s risk. We will call them patient A and patient B.

Patient A tests using a biomarker panel, and his/her result is

• High p-tau217 - This shows that the patient is at risk for Alzheimer’s

• High GFAP - This shows that the person has neuroinflammation, which can be the main driver of the disease.

• Low NfL - This shows that the brain damage marker is low.

Patient B tests using a biomarker panel and his/her result is

• High p-tau217 - This shows that the patient is at risk for Alzheimer’s

• Low GFAP - This shows that the person has low neuroinflammation.

• High NfL - This shows that the brain damage marker is high and possibly could be the main driver of the disease.

They both tested for p-tau217, but the underlying root causes that could be driving their disease are different. Patient A’s main issue is increased neuroinflammation, and this could be the main disease driver. A possible treatment option could be a drug like diranersen (Biogen, BIIB080) that helps to clear the toxic tau and a drug or lifestyle changes that focus on neuroinflammation.

Patient B, on the other hand, has a high brain damage marker. This suggests a different root cause and calls for a different treatment plan. Diranersen will still help remove toxic tau, but identifying the root causes driving the disease and options beyond it is needed to properly manage and prevent disease progression.

This is a perfect example of why root causes could decide which treatment package for each patient. The right treatment plan depends on what’s actually driving the disease in each individual.

Please note: Diranersen is still investigational and it’s currently in Phase 2 trials and expected to move to Phase 3. I’m including it here as an example of the kind of targeted treatment this subtyping approach could point toward, not as something available today.

Other Biomarkers

Scientists are researching and discovering more biomarkers. A good example is Circular RNA (circRNA), which I discussed recently.

In this study, circRNA alone (AUC 0.945) outperformed p-tau217 alone (AUC 0.877).

When the researchers combined circRNA with p-tau217, the accuracy improved over just one biomarker alone (AUC 0.977)

This accuracy was almost as close to the traditional CSF/PET scan imaging used for Alzheimer’s disease risk prediction, but without the invasive side attached to it.

This is the reason why I have been advocating for multiple biomarkers for a more accurate and better diagnosis of Alzheimer’s risk. Plus, it can also help us understand root causes and what is driving the disease.

Bottom line

• Alzheimer’s is not one disease. It is not one-size-fits-all.

• One biomarker test is not enough.

• There will not be one universal cure.

Fuel my day 😊☕

Metformin failed so badly that researchers stopped giving it to patients partway through the trial. Fluvoxamine, on the other hand, significantly cut fatigue scores, and the benefit held steady all the way through day 90. Researchers found a 99% statistical probability it outperformed placebo.

🧬 Why it works
This has nothing to do with depression or serotonin. Long COVID triggers a hidden wildfire of inflammation inside brain cells. Fluvoxamine is a potent agonist of the Sigma-1 receptor, a cellular “master key” that helps quench that inflammation and protect cells from post-viral burnout. This trial didn’t test the mechanism directly, but it’s the leading explanation for why this cheap drug is outperforming the alternatives.

💊 The part that surprised me most
Fluvoxamine actually had fewer side effects than the placebo pill in this trial. So if a $4-a-month generic beats a diabetes drug, and does it more safely, what’s stopping it from becoming standard of care?

👇 If you're a clinician or patient dealing with long COVID: what do you think is holding this drug back from wider use? Genuinely want to hear different takes on this.

Marcus is 64 years old, and he has been feeling tired recently. He looked outside the window and told himself he was just getting older.

Marcus used to be an avid walker. He could run up the stairs to his apartment and still have ample energy to do some household chores or even run on the treadmill. But now he gets winded even halfway up the stairs. Every Saturday he used to look forward to that walk in the park with his grandson. But now just thinking about walking to the park makes him tired. He had started to decline invitations from friends and family, not just because he felt tired, but because he did not want to attend the gatherings, look tired in front of everyone, and bring the festivities down.

Marcus mentioned the tiredness to his doctor, Dr. Bell, during a routine doctor’s appointment. Dr. Bell looked away from the computer he was busily typing on and narrowed his eyes. A series of questions followed. “Are you sleeping well? Are you following the diet I recommended? Are you active?” Marcus said yes to everything. Then he was asked whether he had considered that retirement can be a difficult adjustment. Marcus inclined his head, then slowly closed his eyes and nodded. The visit moved on.

Nothing in the doctor visit seems unreasonable. On the outside looking in, a man in his 60s who has just stopped working could have many physical and emotional burdens that could add stress and fatigue. In other words, there are many ordinary explanations available to describe the way he feels. That is exactly the problem with iron deficiency and the symptoms attached to it. They all have ordinary reasons as explanations.

Tired? You are busy, or you are older, or you are not sleeping well.

Hair coming out in the shower? You are forty-eight, and that happens.

Foggy, forgetful, losing the end of your own sentences? Everyone is foggy. Everyone is on their phone too much.

Breathless on a hill you used to run? You have had a hard training block, or you are getting older too, in your own way, and you should probably rest.

Each of the above dismissals is individually defensible, because most of the time when we feel tired it might not be linked to iron deficiency. The same with hair shedding, which might not be linked to iron. The trouble is not in any one dismissal. It is in what the dismissals do when you add them up, and understanding that requires seeing four things about how symptoms actually behave.

The first is that symptoms overlap across conditions.

There is no symptom on the iron deficiency list that belongs only to iron deficiency. Fatigue, breathlessness, poor concentration, low mood, hair thinning, and cold intolerance are each shared by a dozen other conditions, from thyroid disease to depression to sleep apnea. No single one of them points anywhere on its own, which is exactly why each can be assigned an innocent explanation the moment it comes up.

The second is that they do not arrive as a checklist.

When you read about iron deficiency online, the symptoms are set out neatly, ten of them, one after another. You scan it, you find that two of them sound like you, and you draw the natural conclusion: two out of ten is not a match, so this probably is not me. You disqualify yourself, because you assume that having the condition means having the whole list.

But the list you read is not a set of boxes that will all be ticked at once. A written article online will show ten symptoms side by side, as if they were meant to arrive together, and in a real body they almost never do. A deficiency does not switch on overnight. It develops slowly, over months and often years, and the symptoms surface gradually, one at a time.

• The cold hands come first, two winters ago, and become your normal.

• The fatigue arrives a year later and becomes your normal too.

• The hair follows after that.

Each one settles in on its own before the next appears, so at any given moment you are only ever aware of the one or two that happen to be loud right now, not the trickle that has been accumulating the whole time.

The third follows the second point above.

Because they appear gradually and separately, you underreport them without meaning to. You mention the two that happen to be bothering you this week. You do not mention the cold hands, because that started two winters ago and you have stopped thinking of it as new. You do not mention the hair, because that feels like a separate issue for a separate appointment. You do not connect the restless legs to any of it. So you report two symptoms when, if someone sat you down and read you the full list, you might recognize six or eight of them. That gap between what you have experienced and what you actually say out loud is where the diagnosis quietly goes missing.

The fourth is what all of the above does at the doctor’s appointment.

Two mild, common complaints do not raise an alarm. A busy clinician in a fifteen-minute appointment will not connect two mild complaints to iron, because two nonspecific symptoms are the most ordinary thing to walk through a door. They might connect dots for more obvious patients such as a pregnant woman, or an older individual, but never for seemingly healthy younger adults. And a routine blood panel does not necessarily rescue the situation, because a standard count can read normal while stores are already empty, which is the whole subject of the previous piece. So the picture is never assembled. It is taken apart faster than it can be built, complaint by complaint, appointment by appointment.

This is not a small point about assumptions and mistakes we make. This outlines how serious conditions go undiagnosed until late. The same slow, scattered, easily dismissed symptoms that hide an ordinary iron deficiency can also hide dangerous diseases. In fact, iron deficiency is sometimes the first sign of conditions such as gastrointestinal bleeding, colon cancer, or severe malabsorption disorders like celiac disease. And even diseases such as Alzheimer’s and Parkinson’s diseases. A shortage dismissed as no big deal can actually be the first warning sign of something not trivial at all. This is why seeing the full picture matters. The goal of learning these symptoms isn’t to diagnose yourself, but to share everything you’ve noticed with your clinician, not just the symptoms that feel most urgent right now.

This piece is about what iron deficiency actually does to a person: not the diseases that cause it, which come later in this series, but the experience of the shortage itself. And more usefully, it is about which of these symptoms are generic noise and which few genuinely raise the odds that iron is the answer. That sorting is the part almost nobody does, and it is the difference between walking into an appointment with a vague complaint and walking in with something a clinician can work with.

Why it shows up everywhere at once

In the first piece in this series, we looked at what iron actually does, and the short version is that it is not a blood mineral. It is infrastructure. Iron carries oxygen, but it also runs the machinery inside your cells that converts fuel into usable energy; it is required to manufacture dopamine; it is needed to build DNA in tissues that divide quickly; and it is required to stabilize collagen.

All the infrastructure components I mentioned above are why the list of iron deficiency symptoms looks so scattered. If iron did only one thing, running low would cause one clear problem, and it would be easy to spot. But iron does all of those things at once, so running low does not break one thing loudly. It wears down many things quietly, all at the same time, and no single one of them is alarming enough on its own to make you stop and take it seriously. What follows is that slow wearing down, sorted by where it shows up.

The general cluster.

Fatigue, weakness, low energy, breathlessness when you exert yourself, pallor, cold hands and feet, dizziness, headaches, and a heart that races when it has no reason to. This is the cluster everyone associates with low iron, and it comes from two shortages happening together. Less oxygen is reaching your tissues, and less energy is being made inside the cells once the oxygen gets there.

The fatigue, weakness, and low energy are real, but they’re the part people find hardest to explain to a doctor because they’re not ordinary tiredness. Sleeping 7 to 9 hours every night does not fix it, a weekend away from home or work does not fix it, and an extended holiday does not fix it. People experience the same symptoms: a heaviness they carry around, or the feeling that everything they do now takes more out of them than it used to.

The cognitive and neurological cluster.

Brain fog, poor concentration, memory lapses, difficulty holding attention, and restless legs.

Erin, from the last article, is 27 years old, runs long distance, and noticed the physical side first because her training log made it impossible to miss. Paces that felt easy in the spring had become hard work by midsummer. Her heart rate on gentle runs climbed by ten beats and simply stayed there. But the part that unsettled her more had nothing to do with running. She could no longer read for an hour without losing her place in her own thoughts. And at night her legs would start to crawl, a sensation she could not quite describe and could not hold still against, so she lay there moving them to make it stop.

When she finally had her blood tested, the result came back normal, and she was told she was fine. She was not fine. The reason her test looked reassuring is the whole subject of the last piece: your iron stores run empty long before your blood count drops, and the symptoms start in that gap, while the standard test still reads normal.

The psychological cluster.

Irritability, low motivation, apathy, anxiety, and low mood. This one deserves more attention than it gets, because it is where the wrong explanation does the most damage. Iron is needed to make dopamine, the brain chemical behind motivation and drive, so a person running low does not just feel tired. They feel like they no longer care about things they used to care about. Now picture that in a 64-year-old man who has just retired. The explanation almost writes itself. Marcus was asked, kindly and reasonably, whether he might be a little depressed. Nobody asked what his iron stores were.

The skin, hair, nails and mouth cluster.

Hair that thins and sheds more than it used to, nails that turn brittle or flatten and curl up at the edges, skin that is dry and itchy, skin that tears easily and is slow to heal, cracks at the corners of the mouth, and a tongue that goes sore or oddly smooth. These show up because iron feeds the tissues that renew themselves fastest, and because your body cannot properly build collagen without it. This is also the cluster people are most likely to take to a pharmacy or a salon rather than a doctor. It is worth its own section, and it gets one below.

The appetite cluster.

An appetite that fades, and cravings for things that are not food. This one gets its own section too, because the way it works is genuinely cruel.

The appetite loop

Amara is 31 and pregnant with her first child, which puts her in one of the few situations where the body needs iron faster than at almost any other time in adult life. A growing baby draws heavily on the mother’s supply, and by her second trimester it was showing. She was pale in a way her sister noticed before she did. She felt lightheaded standing up from a chair. At night she could feel her own heartbeat.

What she could not explain was that she had stopped wanting to eat. It was not the nausea, which had passed weeks earlier. It was that hunger simply did not arrive when it should have, at meals she knew her body needed.

This is one of the loops, and it’s a detail most explanations of iron deficiency leave out. Hunger isn’t a matter of willpower. It’s a biological signal your body sends, primarily through a hormone called ghrelin, which tells you when to eat. When iron is low, this signal is disrupted, and your body suppresses the message to eat. As deficiency worsens and turns into anemia, another problem appears: the blood carries less oxygen, so your body starts prioritizing vital organs like the heart and brain, redirecting blood away from the stomach and gut. Digestion slows down, and eating can feel burdensome or unappealing.

Taken together, these effects are almost unfair: the deficiency quietly switches off the very appetite needed to correct it. The person who most needs to eat is the one least able to feel hungry. This matters not just for understanding iron deficiency itself, but because it challenges the usual advice that it’s simply a matter of eating better. Someone caught in this loop isn’t being careless or lazy about their diet—the thing they’re being told to fix has, in fact, switched off their hunger.

The skin story, and why it is not cosmetic

Sofia is 34 years old and has worked in commercial kitchens since she was 19, which gives her an unusually good excuse for the state of her hands.

Cuts that used to close in a few days had started taking weeks. The skin over her knuckles split and stayed split. The corners of her mouth cracked and would not settle, and she treated them as a chapped lip problem for most of a winter. Her forearms itched constantly, and her skin had become dry in a way no amount of the thick unscented cream she kept by the sink seemed to touch. She had a ready explanation for all of it, because kitchen hands are supposed to be wrecked. Heat, water, blades, and repetition will do that to anyone.

The explanation was available, plausible, and wrong.

Iron is required to build collagen. Two enzymes, prolyl hydroxylase and lysyl hydroxylase, cross-link and stabilize collagen so that it holds, and both of them need iron to work, along with vitamin C. Collagen is the structural protein of skin, of the walls of small blood vessels, and of the tissue that closes a wound. When it cannot be properly assembled, skin becomes fragile and tears more easily, small vessels become less robust, and healing slows because healing is largely a matter of laying down new collagen.

That is why this cluster is not a beauty complaint. Fragile, itching, slow-healing skin is a structural tissue problem that happens to be visible, and its visibility is the useful part, because it is one of the few things on this list a person can actually see.

It carries one more lesson, which the treatment chapter will return to. Iron does not work alone here. Collagen synthesis needs iron and vitamin C together, and it needs adequate protein to have anything to build from. Anyone whose intake is low across the board is short of all three at once, and correcting only the iron will only ever fix part of it.

The tells that could tilt toward iron.

Here is the part that matters most, and the reason this list is worth more than a symptom checker.

Almost everything above is nonspecific. Fatigue, low mood, poor concentration, breathlessness, and headaches are the least discriminating symptoms in medicine. They belong to thyroid disease, sleep apnea, depression, heart failure, chronic infection, several other anemias, and simply being under enormous strain. If you walk into an appointment with fatigue and brain fog, you have described something true and pointed nowhere in particular.

But a handful of symptoms do tilt the odds specifically toward iron. They are worth knowing by name, because naming them out loud changes what happens next.

Craving and chewing ice. This is the most specific of them all. Pica is the term for craving substances that are not food, and while it can extend to things like clay, starch, or paper, the compulsive chewing of ice, called pagophagia, is the version most closely tied to iron deficiency. It is also the one people are least likely to report, because it does not feel like a symptom. Diane, whose case opened this series, kept a cup of crushed ice on her desk and worked through it all day. She had been doing it for over a year. She mentioned it to Dr Whitfield almost as a joke, and it was the detail that most sharpened the picture.

Spoon-shaped nails. Nails that flatten and then curve upward at the edges, a change called koilonychia. It is uncommon, it takes time to develop, and it is meaningful when present.

Cracks at the corners of the mouth. Angular cheilitis: splits at the mouth’s corners that persist and resist the usual remedies.

A sore or smooth tongue. Glossitis, where the tongue becomes tender and loses its normal surface texture.

Restless legs. An urge to move the legs, worse at rest and worse at night. The link between restless legs and iron is one of the strongest in this entire field.

Hair thinning and a heart that races on exertion.

Hair thinning and a racing heart during exercise aren’t as specific as the other signs, but they matter more when they show up together.

None of these symptoms can give you a definite answer. That’s important to remember. Spoon-shaped nails don’t mean you definitely have iron deficiency, and neither does craving ice. Each of these things can happen for other reasons, and sometimes iron deficiency shows up with no obvious signs at all. What these symptoms do is raise the chance enough that it’s worth getting a specific test, rather than just being reassured everything is fine.

They could point to iron deficiency. But they do not confirm it.

What symptoms cannot tell you?

If you recognize yourself in much of this, the next honest step isn’t to reach for a supplement. It’s to get a blood test that includes ferritin. Interpreted alongside an inflammatory marker, this will clarify exactly what to ask for, as we’ll discuss later in this series.

Because here is the limit of everything above: symptoms can tell you that something is wrong. Some can suggest that iron is a strong candidate for the cause. But none of them can tell you why you’re low.

And that’s the crucial question, because iron deficiency isn’t a diagnosis—it’s a finding that demands an explanation. Diane, Marcus, Erin, Amara, and Sofia are all running short, but for entirely different reasons. Some are trivial; at least one is serious.

There are only four ways a body can end up short of iron, plus one situation that looks like a shortage but isn’t. That’s the next piece.

This series is educational and is not medical advice. It is written to make your conversation with a clinician better, never to replace it. The people described here are fictional composites.

Fuel my day 😊☕

The most surprising result was that the lowest dose appeared to perform best. That created an important scientific complication: the trial was designed to show that higher doses would produce greater benefits, but the results did not follow that pattern. Technically, the trial missed its primary endpoint, even though the biomarker and cognitive findings were encouraging.

We also discuss the reported safety results, including the absence of ARIA cases commonly associated with some amyloid-targeting treatments, and why the findings still need to be confirmed in Phase 3 testing.

The CELIA data had been presented at AAIC but had not yet been peer-reviewed or published in a medical journal at the time covered by this episode.

This is an educational discussion, not medical advice. Diranersen is an investigational drug and should not be considered an approved treatment for Alzheimer’s disease.

Erin Kovach stopped running three miles from her apartment, which was unusual for her.

She’d been a runner since she was 14 years old. First came cross country, then road races, and finally the steady, unspoken daily training that serious runners just quietly build into their lives. Over the years, she had learned exactly what tired felt like, and she knew how to handle a bad day. But the fatigue she’d been carrying recently was different. It wasn’t either of those things.

Halfway up a hill she had climbed four times a week for six years, her legs suddenly turned to wet sand. Her heart started slamming against her ribs as if she were sprinting. Something was wrong. She stopped, stood still for a moment, and looked up at the drifting morning sun. She let out a quiet sigh, turned around, and started walking home.

Her phone buzzed in her armband on the way. It was the patient portal from her medical provider. It was her doctor, Dr. Blaire. Her results were back.
“Labs look normal — nothing to worry about! Hemoglobin is fine. You’re not anemic”
She read it twice. Then she walked the rest of the way home, in the dark, feeling every step of it.

Here is the thing about that message. Every word in it was true. And it was still the wrong sentence.

Three Words, Used As One

Most people throw around terms like low iron, anemia, low ferritin, and low hemoglobin as if they all mean the exact same thing. Even busy doctors use them interchangeably as shorthand during a hectic afternoon. But they actually describe very different medical issues. It’s in the gray area between those diagnoses where people like Erin get left behind.

So let’s get to know what they mean, what you read on your lab report when it comes to your iron level. Because knowing your iron level can mean many things from

1. Let’s add more steak

2. Let’s add more iron supplement

3. Ok … something is not right. Let’s do more tests to see what it is.

Read more

A fast-moving outbreak of cyclosporiasis, an intestinal illness caused by the microscopic parasite Cyclospora cayetanensis, has become one of the largest on record in the U.S., and it is still growing. But if you have seen the numbers reported anywhere from “1,600 cases” to “nearly 7,000,” you are not misreading. Those figures are all real. They just measure different things. Here is what is actually known, and how to make sense of the parts that sound contradictory.

A note on dates. Case counts in this piece are as of the CDC's July 14, 2026, advisory. The source confirmation came later, on July 17, and is dated separately in that section. This is an active investigation, and the numbers move daily.

Why are you seeing three different numbers?

This is the part most coverage skips. As of July 14, the CDC has confirmed 1,645 cases in the lab. Another 5,100 or so are reported but still being checked. Add them, and you get the “nearly 7,000” in the headlines.

None of those numbers is wrong. They are just measuring different things. 1,645 is what has been confirmed. 7,000 is the outer edge, and some of those pending cases will not pan out. The real figure sits between the two and is still climbing, because Cyclospora takes weeks to confirm, and reported cases always lag the actual infections. So when you see a scary round number, check whether it means confirmed or suspected. With this parasite, that gap is wide, and it is the whole reason the count keeps jumping.

The scale

Michigan is the epicenter, reporting 3,309 cases as of July 14, more than double its count from four days earlier. Nationally, cases span 34 states, with 141 hospitalizations and no reported deaths. Even the confirmed count has already passed the previous U.S. record of roughly 4,700 cases, set in 2019, and a CDC official said that week she expects numbers to keep rising through the outbreak season, which typically runs through August.

For scale, during the same period in 2025, the CDC had received 249 reports of domestically acquired cyclosporiasis. This year, there are 1,645 confirmed cases, with thousands more pending.

The source, now confirmed

For weeks, lettuce was only a suspect. That changed on July 17. The FDA’s traceback investigation identified a single supplier, Taylor Farms de Mexico, as the source of shredded iceberg lettuce served at Taco Bell locations in Indiana, Kentucky, Michigan, Ohio, and West Virginia. The FDA told consumers not to eat it, and Taylor Farms began voluntarily removing all iceberg lettuce sourced from central Mexico, with a recall to follow. Taco Bell says it has removed the affected lettuce from its restaurants nationwide.

The epidemiology behind that call is worth seeing. Across those five states, 1,644 people who got sick reported eating at Taco Bell, with 94 hospitalizations and no deaths. Michigan interviewed 190 of them about what they actually ordered, and 90 percent had eaten iceberg lettuce. The traceback then converged on one supplier, and Taylor Farms says the FDA pointed to a specific independent farm representing under 1 percent of the U.S. iceberg supply.

That cluster is about 1,644 cases. The national count is close to 7,000. So roughly five thousand illnesses still have no confirmed source. Michigan has said plainly that many of its sick residents never ate at Taco Bell, though lettuce kept showing up in their food questionnaires anyway. And lettuce is not the only food this parasite travels on. Past U.S. outbreaks came from raspberries, basil, cilantro, snow peas, and green onions.

One more detail worth knowing. This is not Taylor Farms’ first cyclospora outbreak. In 2013, 631 people across 25 states were sickened by a salad mix traced to the same company, many of them diners at Olive Garden and Red Lobster.

Why is it so hard to trace?

You might wonder: with thousands of cases, why can’t investigators just find the source?

Here is why. Cyclospora has an unusually long, variable incubation period. Symptoms usually appear about a week after exposure, but anywhere from 2 to 14 days out. That delay makes it hard for sick people to remember what they ate, which is a big part of why traceback for this parasite crawls. It is also why the case count keeps climbing after the fact. People infected in June are only now showing up in the data.

What it does to the body

The hallmark symptom is watery, sometimes explosive diarrhea, along with cramping, fatigue, nausea, and loss of appetite. The illness can last for weeks and is known to relapse, improve, and then return before fully resolving, which catches people off guard when they expect a single bout.

It is rarely life-threatening, and most people recover with a course of the antibiotic Bactrim (trimethoprim-sulfamethoxazole), along with hydration and rest. Older adults, young children, and immunocompromised people are generally at higher risk of a more prolonged illness, so symptoms are worth taking seriously in those groups.

A note on the images: why you only ever see the “egg,” not the parasite

If you look at the peer-reviewed images, you will notice they almost always show oocysts, the parasite’s tough, dormant, egg-like stage, rather than an active, wriggling organism. There is a genuinely interesting reason for that.

First, a terminology flag worth keeping straight: an oocyst is not the same as an oocyte. An oocyte is an immature egg cell in reproductive biology. An oocyst is the environmentally armored spore stage of certain parasites. They sound nearly identical and get swapped constantly, but they are unrelated. The Cyclospora stage is the oocyst.

Three reasons the oocyst is what gets photographed:

• ● It is the only stage that survives outside the body. The replicating forms (sporozoites, meronts) are obligate intracellular. They only live inside the cells lining the small intestine. Once shed in stool, only the armored oocyst survives the open environment. In fact, a freshly shed oocyst is not even infectious yet. It has to spend days to weeks maturing in soil or water first, which is precisely why the infection spreads through contaminated food and water rather than person to person.

  ● It is the diagnostic smoking gun. Because the replicating stages remain locked within intestinal tissue, labs diagnose cyclosporiasis by detecting oocysts shed in stool. They are a distinctive 8 to 10 micrometers across, and they autofluoresce, meaning they glow under UV light, which makes them identifiable under a microscope.

• ● Seeing the active parasite requires a biopsy. To photograph the replicating stages actually invading cells, you would need an invasive intestinal biopsy. Those images are rare in the literature. Oocysts, by contrast, are easy to collect from stool or a contaminated leaf.

On washing, the part nearly everyone gets wrong.

Here is the counterintuitive one: rinsing does not reliably fix this. Cyclospora resists chlorine and standard produce washes, and officials have been explicit that this includes home remedies like vinegar soaks. There is no evidence that soaking removes the parasite. It has to be physically scrubbed off or cut away, not soaked or rinsed off. Cooking greens to at least 158°F (70°C) is the only method confirmed to kill it outright.

Practical steps

• Buy whole heads of lettuce rather than pre-washed, bagged mixes. This is the current recommendation.

• Discard the outer 2–3 leaves before use.

• Rinse each inner leaf under cool running water, gently rubbing to dislodge residue.

• Spin dry or pat with a clean towel. Excess moisture encourages bacterial growth.

• Use greens within a few days; store, wrapped in a paper towel, in a bag in the fridge.

• Cook greens (sautéing, wilting) for extra caution. Heat is the only confirmed method of killing.

• Wash your hands, cutting boards, and knives after handling raw produce.

The bottom line

This is an active investigation, with case counts changing daily and only one confirmed product recall so far. If you develop sudden, persistent diarrhea, see a doctor for a stool test rather than waiting it out, especially given how long it can drag on if left untreated.

The reasonable move right now is not to panic or swear off produce. It is to handle greens carefully, stay alert to updates, and treat any single scary-sounding number with the context it deserves.

Fuel my day ☕

The video abive is made based on data provided on July 14th 2026. Please note the updated changes in the current article.

Sources

Primary:
FDA, Investigation of 5-State Outbreak of Cyclospora Illnesses, Iceberg Lettuce (July 2026)
CDC Health Advisory Network Notice, HAN 531 (July 14, 2026)
CDC Cyclosporiasis Surveillance page
MDHHS Infectious Disease Outbreaks page

News coverage:
CNN, Taylor Farms pulling iceberg lettuce after tie to cyclospora outbreak (July 16, 2026)
NBC News, FDA names source of cyclosporiasis outbreak (July 17, 2026)
CBS News, Outbreak traced to lettuce from Mexico used by Taco Bell (July 17, 2026)
STAT News, Outbreak traced to Taylor Farms lettuce, Taco Bell (July 17, 2026)
NBC News, earlier outbreak coverage, including vinegar-soak guidance (July 14, 2026)

Peer-reviewed:
Ortega and Sanchez, Clinical Microbiology Reviews (2010)

Diane is 48, and she has been tired for the better part of two years.

Not an ordinary kind of tiredness. It’s the kind sleep doesn’t touch. She takes the stairs at work and arrives at the top with her heart going like she’s been running. Her hair is coming out in the shower. She’s cold when nobody else is cold. Her brain buffers in the middle of her own sentences. For a long time, she assumed it was work, or age, or both, because that’s what everybody kept telling her it was.

Eventually, she pushed for blood tests. Now she’s sitting in an exam room while her doctor, Dr. Whitfield, works down the results, ruling things out as she goes.

Thyroid — fine.

Blood sugar — fine.

Kidneys, liver, inflammatory markers — nothing jumping out.

Then she stops.

“Your iron is low. Your stores look quite depleted. That could explain a lot of this.”

And Diane feels a flood of relief, because at last there’s a name for it, and because she already knows what to do about it. She’s seen the ads. She’s read the posts.

“Okay,” she says, reaching for her bag. “So I’ll get an iron supplement. Eat more red meat, more spinach. Right?”

Dr. Whitfield does not reach for the prescription pad.

“Not so fast,” she says. “Let’s slow down.”

Diane looks up.

“Low iron isn’t the answer. It’s the question. Something is making you low — and until we know what that something is, eating more steak isn’t going to stop it. It may just make the number look better while whatever’s causing it carries on underneath. I don’t want to treat this yet. I want to understand it first.”

Diane’s instinct is the instinct almost everybody has. It’s also the instinct the wellness industry has spent a fortune reinforcing. Symptom, supplement, done. It’s a tidy little loop, it sells extraordinarily well, and it is very nearly useless.

Because iron deficiency is a symptom, not a diagnosis. It’s smoke.

And the useful question is never, “How do I get rid of this smoke?”

It’s always: what’s burning?

First: why does low iron make you feel bad in so many different places?

Look again at Diane’s list. Exhaustion. A racing heart on the stairs. Hair in the drain. Cold hands. A brain losing the end of its own sentence.

Those don’t look like they belong together. Which is exactly why she spent two years being told they were five separate problems — or, more often, no problem at all.

Tired? You’re busy.

Hair thinning? You’re 48.

Foggy? Everyone’s foggy.

They cohere the instant you understand what iron actually does.

Most people believe iron equals hemoglobin — that iron is a blood thing, full stop. That isn’t close to true. Iron isn’t one system’s mineral. It’s infrastructure. And infrastructure doesn’t fail politely in one place; it fails a little bit everywhere, in ways that are easy to dismiss one at a time and impossible to dismiss together.

It carries your oxygen.

Two-thirds of your iron sits in hemoglobin (your red blood cells), grabbing oxygen at the lungs and handing it out to your tissues. Run low, and you make fewer, smaller, paler red cells — less cargo space, fewer trucks. That’s the breathlessness, the pallor, and the heart racing on the stairs, because a heart short of oxygen-carrying capacity compensates the only way it can: by beating faster.

That’s the part every article gets right. It’s also the least interesting part.

It runs your mitochondria.

The machinery that turns fuel into ATP — the energy you spend to think, move, heal, hold a thought- is built from iron-sulfur clusters and iron-containing proteins. Iron isn’t a bystander in your energy production. It’s a working part of the engine.

This is the bit that gets left out, and it explains something important: if iron only mattered for oxygen delivery, you’d expect to feel fine until your blood count dropped. But that isn’t what happens. People are flattened or tired long before their anemia is severe. And some are flattened, even though their blood counts still read perfectly normal.

The problem isn’t only in the delivery van. It’s at the power plant.

Which is why this tiredness has a quality people struggle to describe to a doctor. It isn’t sleepiness. Sleep doesn’t fix it. A holiday doesn’t fix it. It’s the feeling of running an engine that can’t make enough power; everything is harder than it should be, including the things that are supposed to be free.

It makes your dopamine.

Iron is the rate-limiting cofactor for tyrosine hydroxylase, the enzyme that manufactures dopamine. Rate-limiting is the key phrase: when iron runs short, the production line slows, no matter how much of everything else is available. Dopamine governs attention, motivation, reward, and movement. Iron also supports serotonin and norepinephrine, and builds the myelin that insulates your nerves.

So a brain short on iron isn’t just a tired brain. It’s a brain running a sluggish dopamine system — the thread connecting iron to brain fog, poor concentration, flattened motivation, irritability, and restless legs. (That opens a set of questions big enough to need their own article. We’ll get there.)

It builds fast-dividing tissue in our body.

The enzyme that supplies the raw material for new DNA is iron-dependent, so the tissues that divide fastest in our body pay the price first: bone marrow, gut lining, hair follicles, nail beds. It’s a queue. The hair in Diane’s shower drain isn’t a vanity complaint. It’s a signal from a tissue that has run out of raw material.

It holds you together.

The enzymes that stabilize collagen need iron and vitamin C, which work in tandem. Short on either, and the scaffolding gets built badly — dry, itchy, fragile skin; wounds that heal slowly; cracks at the corners of the mouth. These are the symptoms people are least likely to connect to iron and most likely to be sold a cream for.

And it does more than that.

Thyroid hormone production is iron-dependent, so deficiency can worsen an underactive thyroid and mimic one. Immune cells need iron to multiply. Iron helps regulate body temperature, which is the cold intolerance. It even interacts with ghrelin, the hunger hormone — so deficiency can blunt the very appetite that might have corrected it.

Finally — the master switch.

Your liver stores iron as ferritin. Your body recycles about 20–25 mg a day from worn-out red cells and puts them straight back to work. Against that, you only need to absorb 1 to 2 milligrams a day from food to maintain that level.

One to two milligrams. That’s the whole daily requirement. Your body is not running a deficit because you skipped a steak.

And governing all of it is a single hormone: hepcidin. It decides whether iron gets absorbed and released, or locked in the vault where you can’t reach it. Remember that name. It’s about to matter.

So: not five unrelated problems. One shortage, felt everywhere at once.

Your body doesn’t just run low for no reason.

This is the hinge of the whole argument.

Your body is exceptionally good at holding on to iron. It recycles it relentlessly. It hoards it. It needs a trickle a day. It runs an entire hormonal system whose only job is guarding the supply.

So when the tank is empty, that emptiness means something. It isn’t bad luck. Something has gone wrong upstream — iron isn’t getting in, or it’s blocked on the way through, or it’s leaking out, or the body is burning through it faster than it can be replaced.

Which is why “eat more red meat” is such a strange piece of advice once you look at it squarely. It only helps if the problem was that you weren’t eating enough iron in the first place. If your gut can’t absorb it, more steak won’t fix anything. If you’re quietly bleeding somewhere, more steak won't fix it. It’s like pouring water into a bucket with a hole in it and calling it a solution.

The first useful question is never how do I get more iron. It’s: which of these is actually happening to me?

The four doors

Almost every cause of iron deficiency walks through one of four doors. Plus one impostor who doesn’t use a door at all and is the reason so many people get misread.

Door One — Not enough coming in.

The intake door. The only one a steak can close. Low-heme diets, vegetarian and vegan eating, but also the quiet drift of somebody who simply stopped eating much red meat a few years ago and never noticed. Restrictive dieting. Poor appetite due to age or illness. Appetite-suppressing drugs, including the GLP-1 medications now taken by enormous numbers of people, where intake can collapse without anyone tracking what’s been lost.

The honest note: if this is your only open door, then yes — food and supplements may well fix it. The point isn’t that diet never matters. It’s that you can’t know this is your door until you’ve checked the other three.

Door Two — Coming in, but not absorbed.

You can eat a perfect diet and absorb almost none of it. Behind this door: coeliac disease, which can stay silent for years with iron deficiency as its only outward sign. Autoimmune gastritis. Low stomach acid. Long-term acid-suppressing medication, the reflux drugs millions take daily, and stop thinking of them as drugs at all. H. pylori. Previous gut surgery, including bariatric surgery. Inflammatory bowel disease.

This door explains one of the most maddening patterns in medicine: the person who dutifully takes iron for six months, doesn’t improve, and gets labeled non-compliant.

Door Three — Leaking out.

The most important door, and the most likely to be dangerous. Iron leaves with blood, whether you can see it or not, and mostly you can’t. Heavy menstrual bleeding is comfortably the commonest cause in women of reproductive age and one of the most normalized symptoms in all of medicine. Bleeding in the gut: ulcers, gastritis, inflammation, abnormal vessels, polyps, and cancers, which is why this door gets its own article. Regular aspirin and anti-inflammatory painkillers. Frequent blood donation.

The bleeding that matters most is usually the bleeding you cannot see.

Door Four - Demand outpacing supply.

Pregnancy, where demand climbs steeply, and the stakes extend to the baby. Breastfeeding. Infancy, growth spurts, adolescence. Recovery from surgery or major blood loss. Heavy endurance training.

And the impostor.

There’s a state where the iron is there, in storage, and your tissues are still starving. It’s called functional iron deficiency, and hepcidin drives it. When there’s chronic inflammation anywhere in the body — kidney disease, heart failure, autoimmune disease, obesity-related inflammation, infection — hepcidin rises, and iron gets locked in the vault.

Here’s why that matters more than almost anything else in this series. Ferritin, the standard test for iron stores, also rises with inflammation all on its own. Which means a person can be genuinely iron-starved and still have a ferritin result that reads perfectly normal or high. The test says you’re fine. Your tissues disagree.

This is the common way iron deficiency can get misread, by patients and by doctors. A normal ferritin level doesn’t automatically mean you’re fine.

So what happened to Diane?

Nothing dramatic. Dr. Whitfield didn’t solve it.

She did something better, and rarer: she declined to guess.

She kept asking questions, and two things surfaced that had never been documented in a medical record.

Diane’s periods had become noticeably heavier over the previous couple of years. She’d never thought to mention it because she’d been told, repeatedly, by well-meaning people that this is simply what happens in your forties. It had been normalized into invisibility. That’s Door Three, potentially wide open.

And, almost as an afterthought during the medication review, Diane had been taking a daily heartburn tablet for about six years. She’d long stopped thinking of it as a drug. But that class of medication works by lowering stomach acid — and stomach acid is part of how the body frees iron from food. That’s Door Two, potentially half-closed the whole time.

“Note the word: potentially.”

So Dr. Whitfield didn’t say, “This is what you have.” She said, “This gives us somewhere to look.”

Which means a fuller picture of the iron itself, not one number. It means asking whether that heavy bleeding has a cause of its own. It means asking whether the absorption problem is really the tablet — or whether the tablet is masking something else that’s been quietly damaging her gut lining for years.

We leave Diane there. Not diagnosed. Investigated.

What’s coming

Diane’s story is the common one. Most iron deficiency turns out to be something ordinary, findable, and fixable — and I’d rather tell you that plainly than frighten you into reading on.

But most is not all.

So we will investigate other stories to understand iron homeostasis in our body as the series progresses.

A low iron result is a question. The answer isn’t on a supplement label. But leaving you with the question and no way to answer it would be its own kind of failure — so here’s what’s ahead:

• The vocabulary in this chapter and series is honest. Because deficiency, anemia, and overload are three different things, and they are used interchangeably by people who should know better. And you can be genuinely deficient and genuinely symptomatic, long before a test calls you “anemic.”

• The tests to ask for, and how to read them. We will learn what a full iron panel actually contains, and why a lone ferritin report can lie to you. We will also discuss why a ferritin report must be read, while accounting for inflammation. This might require extra tests to belong on the form, depending on which door is open.

• What must be ruled out, and in what order? Not by how common something is, but by how much it costs to miss it.

• Your actual odds. The likelihood of each cause isn’t the same for everybody. It shifts enormously with age, sex, ancestry, medication, and history. A twenty-six-year-old with heavy periods and a sixty-four-year-old man are not running the same risk, and it does neither of them any favors to pretend otherwise.

• Which groups carry which risks? Pregnancy and postpartum. Perimenopause. Older adults. Vegetarians and vegans. Athletes. Blood donors. People on acid-suppressants, painkillers, or appetite-suppressing drugs. After gut surgery. Children and teenagers. Certain ancestries, where inherited blood traits change how results must be read.

• The look-alikes. Conditions that produce exactly these symptoms without being iron deficiency — and, more treacherously, the ones that both imitate it and cause it.

• The other danger. Too much iron is its own disease. Your body has no efficient way to get rid of the surplus. “More is better” is a genuinely harmful idea.

• What to say at the appointment. The questions, the scripts, and the sentences that turn five minutes into a real investigation.

What this series isn’t

It isn’t a supplement pitch. I won’t be telling you what brand to buy, and I have no interest in the reflex that converts every symptom into a bottle. Where the answer is genuinely simple, I’ll tell you it’s simple — that runs in both directions.

It also isn’t a manual for treating yourself. Please don’t start ironing on the strength of something you read, including this. Iron you don’t need isn’t harmless, and a signal you’ve masked is a signal you’ve lost.

What it is is a way to walk into that exam room already halfway through the conversation Dr. Whitfield started.

Dr. Whitfield was right to slow down.

The rest of this series is about what she looked for next.

Fuel my day ☕

Subscribe to get the whole series — including the deeper pieces on the four doors, the causes nobody should miss, and the appointment playbook.

Educational content, not medical advice — written to make your conversation with a qualified clinician better, never to replace it. Iron should only be started, stopped, or changed with a doctor who knows your full picture. Diane, Marcus, and Dr. Whitfield are fictional composites, assembled from patterns that recur constantly in the clinical literature.

I’ve spent the last stretch buried in the research on iron — reading the literature, following the threads, filling a whiteboard. It turns out to be a bigger, stranger, and more important subject than most people realize, and I wanted to understand it properly before writing a single word of it for you.

A little while ago, I asked what you most wanted me to dig into. 83 of you answered — thank you for that. More than 40% asked for the relevance of iron: more than any other single topic, by a clear margin. So that settles it. For the month of July, we’re doing iron.

The rest of your requests aren’t forgotten. A lot of you asked about magnesium, and a good number asked about mushrooms and other wellness products, what they actually do, and whether you should be taking them at all. Those are coming in the weeks after. I’ve kept every response, and I’m building this around what you told me you need.

Here’s how we’re going to do iron: with the hype stripped out. I want to take what is essential and give you honest feedback about what an iron deficiency actually means. This is not a nudge toward the supplement aisle — I’d genuinely discourage that. And it is not “go eat a steak,” either. Both of those answers skip the only question that really matters.

Because a low iron reading is not the headline. It’s a clue. When a deficiency shows up, the reflex, even for a lot of doctors, is “let’s add some iron and move on.” But adding iron isn’t the thing to be concerned about. The concern is that the deficiency indicates something in the system isn’t right.

Think about it this way.

And it runs the other way, too. Too much iron — over-supplementation — is its own risk, and we’ll cover that just as honestly. More is not automatically better.

So over July, this is the ground we’ll cover, piece by piece, over the coming weeks:

• What iron actually does in the body, far more than “makes blood”, and what it feels like when it runs low, or when there’s too much of it

• The symptoms worth noticing, including the quiet, easy-to-dismiss ones that most people (and plenty of articles) skip right past

• What those symptoms can be linked to, from the everyday (heavy periods, low dietary iron, frequent blood donation) to conditions a deficiency can quietly signal: celiac disease, a slow-bleeding ulcer, H. pylori, a gut that isn’t absorbing properly, and, in some cases, something as serious as colorectal cancer

• Why “just take iron” can be the wrong move, the difference between not getting enough in and not absorbing what you do get, and why that difference changes everything.

• The other side of the coin: too much iron, and why over-supplementation carries its own real risks

• And the piece I care about most: a practical, plain-language list of things to raise with your doctor

I’m not going to pin down an exact schedule for each one, because I follow the science where it leads and sometimes reshuffle along the way. But new pieces will be landing throughout the month, some open to everyone, and some for paid subscribers who want the deeper maps and the full walk-through.

And I’m naming only a few here; there are more, and we’ll get to them through the month. But let me be clear about what this series is and isn’t.

And how the body stores and handles iron across a lifetime is now being studied in connection with some of the most serious conditions we know — cancers, and neurodegenerative diseases like Parkinson’s and Alzheimer’s, among them. A good deal of that is still frontier research, and I’ll always tell you when something is emerging rather than settled, instead of overselling it.

Here’s the practical part, and it’s simple:

That last one — the doctor list — is the heart of this whole thing. By the end of July, you’ll have the questions worth asking, so that if you notice these symptoms, or your doctor finds your levels are low, you can walk into that appointment knowing what to look for, instead of walking out with only a bottle of pills and an unanswered question.

So here’s my invitation: come along for the month. The first piece lands next week, and the rest follow. If you don’t want to miss them, especially the doctor’s list and the deeper dives, make sure you’re subscribed, and each one will show up for you as it goes live.

If you have specific questions, pass them along as well. I will make sure I,

1. Address them in an article.

2. Research and find answers for you and your doctor.

See you next week. Let’s get into it.

This series is health education, not medical advice. Iron matters in both directions — too little and too much can both cause harm — so everything here is meant to make your conversation with a licensed clinician better, never to replace it.

Fuel My Day 😊

I keep getting the same DMs and replies every single week:

“Neuroscope, there are so many Parkinson’s trials right now… which ones actually matter?”

’‘Is anything really working yet?’‘

“One headline says a drug slowed the disease, the next says it failed — I’m so confused.”

Honestly, I get it.

Right now, there are more Parkinson’s clinical trials than at any point in history. But most people have no idea which ones are actually promising, which ones are hype, and why the headlines are so contradictory.

So today, I’m breaking down the confusing details for you and zooming in on what matters.

The honest answer is this:

For decades, Parkinson’s research has asked one big question: How do we replace the lost dopamine?

Now the field has quietly moved on.

To make this real, let’s meet Henry, a hypothetical patient I built as a composite. Every trial, drug, and biomarker I’ll attach to him is real and up to date as of mid-2026.

Henry’s Diagnosis Wasn’t Just “Looks Like Parkinson’s”

Henry is 64. He noticed a tremor in his right hand a few months ago and went to a neurologist, who did a clinical exam.

Most patients stop there: clinical exam + symptoms, then a prescription for levodopa. That approach still misdiagnoses about 25% of cases. Some neurologists will even tell you that you won’t truly know until autopsy. This reality might have been true before. But not anymore.

Henry got lucky. His neurologist, Dr. Patel, went further. She didn’t stop at the clinical exam. She did tests for biological confirmation.

1. She ordered a skin biopsy (three small punches from the neck, thigh, and leg) to look for misfolded alpha-synuclein. The test came back positive with 95.5% sensitivity in validation studies.

2. To further verify, she ordered a DaTscan, which confirmed dopamine transporter loss.

For the first time, Henry didn’t just have a “probable Parkinson’s” label. He had biological confirmation.

If you or someone you love is dealing with a Parkinson’s diagnosis right now, this is the question worth asking your neurologist. These tests exist today.

Other biomarker tests are being evaluated today. The most promising one, which has been fast-tracked, is αSyn-SAA. The FDA issued a formal Letter of Support for αSyn-SAA. This is a unique regulatory tool developed to fast-track clinical drug trials rather than the diagnostic itself.

Beyond αSyn-SAA, clinical trials are evaluating an array of other biological and technical footprints to track Parkinson’s disease (PD). While αSyn-SAA serves as a diagnostic “yes/no” indicator of disease presence, the following markers are actively used in trials to track the rate of brain damage, genetic alterations, and real-world physical decline.

Others being tested (in clinical trials) include Neurofilament Light Chain (NfL), Glial Fibrillary Acidic Protein (GFAP), Insulin-Like Growth Factor 1 (IGF-1), Transfer RNA (tRNA) Fragments, Lysosomal Enzymes (GBA Pathway), BMP (Bis(monoacylglycero)phosphate), Passive Gait and Tremor Metrics, Digital Nocturnal Metrics, Neuromelanin-Sensitive MRI (NM-MRI), Synaptic Vesicle Glycoprotein 2A (SV2A) PET Scans.

Three Findings, Not Three Coincidences

A confirmed diagnosis was not the end of Henry’s workup. His neurologist took a detailed symptom history and ordered bloodwork. Two things stood out that had nothing to do with movement.

1. Henry had lived with constipation and other gastrointestinal issues for almost a decade before the tremor appeared.

2. His bloodwork also showed elevated markers of chronic low-grade inflammation.

Neither finding is unusual in Parkinson’s. Constipation can appear a decade or more before motor symptoms and eventually affects a large majority of patients. Researchers are now testing combinations of biomarkers, such as fecal calprotectin (a marker of gut inflammation), short-chain fatty acid levels, and standard blood inflammatory markers, to identify a “gut-first” pattern.

This distinction has a name in the research literature: body-first Parkinson’s (in which the disease process appears to begin in the gut and spread upward) versus brain-first Parkinson’s (in which it begins in the brain). Same diagnosis on paper. Different disease underneath.

With Henry, we are looking at confirmed Parkinson’s tied directly to a gut-first progression pattern and chronic inflammation that is driving the disease forward. These pieces fit together. A bad mix of gut bacteria triggers inflammation, which in turn damages neurons. If we want to help him, we can’t just chase the tremor on the surface. We have to treat the whole chain of events that causes it. Managing his care means interrupting this destructive loop entirely, not just treating the visible tremor.

What 80 to 90 Percent Neuron Loss Actually Means

Here’s the part of Parkinson’s that doesn’t get said often enough:

This is why standard treatments like levodopa can only manage symptoms. They replace the missing chemical, but they can’t bring back the lost cells.

This is why current research and clinical trials are focusing on replacing the lost cell populations.

The Three Companies Racing to Replace What's Lost

Three stem cell programs are currently in clinical testing to determine whether transplanted neurons can restore dopamine production where the patient’s own cells have failed.

Bemdaneprocel, developed by BlueRock Therapeutics and Bayer, completed a 36-month follow-up on its Phase 1 trial in late 2025. In the high-dose group, patients improved by roughly 18 points on the standard motor scale while off medication, and gained about an extra hour of well-controlled symptom time per day. No tumors formed. No serious adverse events were reported. The data was strong enough that the FDA allowed BlueRock to skip a traditional Phase 2 and move directly into Phase 3, a trial called exPDite-2, which is now enrolling with results expected around 2027.

Kyoto University’s iPSC program, led by Jun Takahashi’s team, published its Phase I/II results in Nature in 2025. The study enrolled 7 patients and followed them for 24 months post-surgery. The patients showed roughly 20% improvement in off-medication motor scores. Crucially, the therapy proved to be highly safe, resulting in no serious adverse events.

Aspen Neuroscience’s Sasineprocel (ANPD001) takes a distinctly personalized approach to Parkinson’s treatment. The company starts with a patient’s own skin cells, reprograms them into induced pluripotent stem cells (iPSCs), differentiates them into dopaminergic neuron precursors, and transplants those cells back into the patient’s brain. Because the therapy is autologous, patients do not require heavy immunosuppressive drugs.

Key advantage:

• No donor cells → no need for heavy immunosuppressive drugs.

• Completely safe with no serious graft-related issues

• Sustained improvements in mobility

• Increased “Good ON time” (+2.1 to +2.4 hours)

• Better MDS-UPDRS scores and quality-of-life measures

For the first time, three different companies, each using a different cell source, are generating real human data, suggesting that replacing the lost neurons — rather than simply replacing the missing chemical — can actually work.

Teams across the world are already testing this concept in new clinical trials. Down the road, this will likely become a standard, normal procedure.

Why Replacing the Neurons Isn't the Finish Line

Here’s the catch that Henry’s neurologist kept in mind from day one: transplanting new dopamine neurons into a brain that is still producing the same conditions that destroyed the original ones is like rebuilding a flooded basement without fixing the leak. The water will eventually return.

If Henry’s gut dysbiosis, chronic inflammation, or other ongoing drivers contributed to the neuron loss, a stem cell transplant by itself won’t stop the disease process. The new cells would be placed back into the same hostile environment that killed the old ones. That’s why true precision care must run on multiple tracks simultaneously, replacing what’s lost while also addressing the underlying factors that caused the damage in the first place. Only then does the treatment have a real chance to change the long-term course of the disease.

Fixing the Gut That Started It

Henry’s “gut-first” pattern aligns with a growing body of research that stretches back more than a decade. A landmark 2015 study found that patients with Parkinson’s had roughly 78% less Prevotella — a protective gut bacterium — than healthy controls, along with higher levels of pro-inflammatory species. This microbial signature has since been replicated across multiple international cohorts. For patients like Henry, three main approaches are now being tested:

• Fecal microbiota transplants (FMT) are being evaluated to determine whether directly restoring bacterial balance can reduce symptoms and slow progression.

• A 2025 randomized trial of a four-strain probiotic showed that it reduced systemic inflammation, accelerated levodopa onset, and eased non-motor symptoms (especially constipation).

• Diet intervention studies are examining whether accessible changes, such as a Mediterranean-style eating pattern, a medical-grade ketogenic diet, can meaningfully shift the microbiome and improve motor scores simultaneously.

None of these approaches claims “fix the gut, cure Parkinson’s.” The real question being tested is more focused and honest: Can correcting the microbiome slow disease progression in the right patients? Early signals are encouraging, but FMT remains experimental and is not yet an approved treatment for Parkinson’s.

Calming the Fire

Henry’s second major root cause — low-grade chronic inflammation — opens an entirely different front in Parkinson’s research. Misfolded alpha-synuclein doesn’t just sit quietly in the brain. It activates a key danger sensor in the brain’s immune cells known as the NLRP3 inflammasome. This, in turn, triggers a cascade of inflammatory signals that appear to accelerate dopamine neuron death.

Two companies recently tested NLRP3 inhibitors in patients with Parkinson’s disease. Ventus Therapeutics’ VENT-02 trial was stopped early, with no public efficacy data released. That outcome doesn’t necessarily disprove the underlying biology — it may simply mean the specific drug or trial design wasn’t optimal. In contrast, Ventyx Biosciences’ VTX3232 has generated what many experts describe as one of the most promising signals in neuroinflammation in recent years.

One drug tanked, while another actually looks promising. That’s just how real clinical research works. It’s messy. But when headlines focus on just one trial at a time, we lose the bigger picture.

What Henry Can Do Without Waiting for Any Trial

None of the advanced therapies discussed earlier is available to Henry in approved form today.

But one of the strongest evidence-based interventions is already available, and it doesn’t require waiting for any new drug approval. What is available is the maintenance layer underneath all of it.

High-intensity aerobic exercise, particularly high-cadence cycling and high-intensity treadmill training, currently has the most robust clinical trial data among non-drug approaches for Parkinson’s. In the SPARX Phase 2 trial (published in JAMA Neurology, 2018), 128 patients with early, untreated Parkinson’s were randomized to high-intensity treadmill exercise (80–85% of maximum heart rate), moderate-intensity exercise, or usual care. After six months, the high-intensity group showed no worsening of motor symptoms, while the other groups declined.

Even more striking are the results from high-cadence cycling studies. Cleveland Clinic researchers found that forced high-cadence cycling (80–90 RPM) produced rapid improvements: roughly 41% reduction in rigidity, 38% in tremor, and 28% in bradykinesia in some patients. In a larger home-based trial (CYCLE-II), patients cycling at high cadence three times per week experienced dramatically slower motor decline — just 0.2 points per year on standard scales compared to 3.9 points per year in the usual-care group.

We discussed some of this in an earlier article.

A 195-patient randomized trial published in the New England Journal of Medicine showed that Tai Chi significantly reduced falls and improved postural stability in patients with Parkinson’s, with benefits persisting for 3 months after the program ended. Another 12-month randomized trial of Argentine tango (62 patients) found meaningful improvements in motor scores even when tested off medication — suggesting the gains were more than just temporary symptom relief.

These benefits appear to go beyond simple symptom relief. Imaging studies have shown that intense exercise can increase dopamine transporter availability in key brain regions, suggesting a possible biological effect on the disease process itself.

Further, clinical trials show that targeted improvements in diet, sleep quality, and sound therapy can significantly reduce Parkinson’s disease symptoms and improve daily quality of life. These are conversations everyone should have with their neurologists.

This is the practical foundation Henry’s neurologist can implement immediately, working with a physical therapist or exercise specialist to design a safe, personalized, high-intensity program that runs in parallel with any future therapies that become available.

The Other Race: Stopping the Protein Before It Aggregates

There’s also a broader, very active front in Parkinson’s research that aims even earlier — preventing alpha-synuclein from misfolding and clumping in the first place. Several candidates are now in mid-to-late stage trials:

• Prasinezumab (Roche): an antibody that binds toxic forms of the protein and promotes its clearance. Now in Phase 2/3.

• Buntanetap tartrate: an oral small molecule designed to stop the aggregation process upstream.

• Blarcamesine (Anavex): works via the Sigma-1 receptor to help cells clear toxic proteins.

• UB-312 (Vaxxinity): an active vaccine that trains the immune system to target misfolded alpha-synuclein.

With more than 60 candidates currently in the pipeline, this represents the most active disease-modifying frontier in Parkinson’s research today.

Henry's Actual Stack

Let’s put it all together. Henry’s hypothetical treatment plan has four treatment options. This is specifically optimized for him, his symptoms, and root causes:

• Replace the neurons that are already gone.

• Repair the gut signals that may have helped drive the disease.

• Protect against ongoing inflammation that could damage both old and new neurons.

• Maintain the gains with diet and high-intensity exercise (especially high-cadence cycling) that already have solid clinical trial evidence.

Skip any one piece, and the others have to work harder, or may not hold up over the long term. This is what precision medicine actually looks like at the level of a single patient.

This Isn't Just About Henry

A patient whose Parkinson’s starts in the brain rather than the gut needs a completely different treatment plan—one built strictly around their own labs and biomarkers.

Neurology is finally moving away from standard, one-size-fits-all prescriptions. Instead, doctors are building layered treatments tailored to a patient's specific biology.

We are seeing this same shift happen with Alzheimer’s and ALS, but Parkinson’s research is further ahead, giving us a blueprint for the future. Henry isn't a real person; he's a composite character used to simplify this massive wave of new data.

For anyone facing a new diagnosis, the best starting point is to follow Henry's initial step. Don't just ask what the disease is—ask your doctor what specific biological mechanism is driving yours.

This is one hypothetical patient, built to make a real and growing body of research legible. If you're navigating an actual Parkinson's diagnosis, the place to start is the same place Henry's care started: asking what specifically is driving your disease, not just naming it.

Fuel the science ☕✨

Medical Disclaimer

The treatment options and precision medicine analysis presented here are based solely on a hypothetical patient scenario and an evaluation of the current Parkinson’s clinical landscape. This content is for educational and informational purposes only and does not constitute formal medical advice, diagnosis, or treatment.

Using or relying on this information does not establish a doctor-patient relationship. Parkinson’s Disease is a highly complex condition, and individual medical situations and genetic profiles vary widely. Therefore, these hypothetical recommendations should not be interpreted as a final treatment plan or standard of care for any individual.

Always consult with a qualified neurologist, movement disorder specialist, or healthcare provider regarding any medical condition or before making changes to a treatment plan. Never disregard professional medical advice or delay seeking it because of information read or evaluated here.

You have already read about why creatine monohydrate is the reference standard for muscle. Three decades of research, one clear answer: “Buy the simple thing”.

But if your reason for caring about creatine goes beyond the gym, and if what you are actually trying to support is your brain, the story gets more complicated. And more interesting.

The last article explained why oral supplementation only raises brain creatine by 5 to 15%, no matter how much you take. The blood-brain barrier has a limited number of entry points for creatine. Those entry points saturate quickly, and flooding your bloodstream with more creatine does not push more of it into the brain.

This article is about what researchers are doing about that ceiling.

In this piece:

• What GAA actually is, and why it is not just another creatine form

• The two-step process your body uses to make creatine, and where GAA fits into it

• What the early clinical trials show, including a study where brain effects showed up in just seven days

• The one safety concern worth knowing about, and the simple reason pairing GAA with creatine appears to fix it

• Women's studies - What a 2026 trial in perimenopausal and menopausal women found, and why it raises a question that the rest of the creatine research has not answered

• My honest assessment of how solid this evidence actually is, and what would need to happen before I would call it settled

Read more

The last article established one clear answer for muscle creatine: plain monohydrate, taken consistently, is what thirty years of research supports. That answer holds. But if your reason for taking creatine goes beyond muscle performance — if you are interested in what it does for your brain — the story changes. The same supplement. A different biological problem. And a ceiling that no amount of standard monohydrate overcomes.

The Transporter Bottleneck

The blood-brain barrier controls what gets into the brain and what does not. Creatine does not get a free pass. It can only cross through a specific molecular gateway called SLC6A8, a transporter protein that sits in the walls of the tiny blood vessels feeding the brain. Without it, creatine cannot get in.

This gateway is rare. It is present in the blood vessel walls and in neurons, but it is missing from astrocytes, the cells that make up much of the brain’s volume. Astrocytes can produce some creatine locally through their own synthesis machinery, but they cannot absorb it from the bloodstream. So Creatine from food or supplements has to find one of those specific entry points and wait its turn.

The gateway also has a maximum capacity. Standard oral supplementation already pushes it to or near its limit. Taking more creatine does not open more gates. There is also evidence that chronic high dosing can cause the brain to reduce the number of available transporters over time as a compensatory response — meaning very high long-term doses may work against themselves. Think of a busy train station with only one working ticket barrier. Doubling the crowd outside does not speed things up. The barrier is already processing as fast as it can.

This is why researchers are no longer asking how much creatine to take for the brain. They are asking how to get around the gateway entirely. That is what the approaches covered later in this article are trying to solve. The ceiling is not a dosing problem. It is structural.

What Oral Supplementation Actually Achieves in the Brain

Dechent and colleagues measured brain creatine directly using magnetic resonance spectroscopy in 1999. They gave 20 grams per day — split into four 5-gram doses — for four weeks, resulting in a statistically significant 8.7 percent increase in total brain creatine averaged across regions in healthy young volunteers. The increase was not uniform: the thalamus showed the largest rise at 14.6 percent, white matter at 11.5 percent, cerebellum at 5.4 percent, and grey matter at 4.7 percent.

Other MRS studies using higher doses have reported increases in brain creatine ranging from 5 to 15%. Getting there takes time. Even the lower end of that range typically needs at least four weeks of consistent supplementation. Muscle creatine saturates within one to two weeks at standard doses. The brain is slower and less complete by comparison.

That 5 to 15 percent increase is real and does appear to influence outcomes in some contexts. But understanding what creatine actually does in the brain changes how you interpret those numbers.

Creatine does not fuel the brain at rest. It acts as an energy buffer — a reserve that gets drawn on when the brain’s demand for ATP spikes suddenly and the normal supply cannot keep up fast enough. Think of it less like adding fuel to a tank and more like adding a backup generator. At rest, when the main power supply is adequate, the generator sits idle. Under stress, sleep deprivation, or intense cognitive load, the generator becomes the difference between the lights staying on and flickering.

Creatine does not make a well-rested brain sharper. What it does is rescue performance when the brain is under pressure — during sleep deprivation, mental fatigue, or intense cognitive demand. That is when the backup generator matters. It also helps explain why cognitive trials show inconsistent results: a study measuring prefrontal function in sleep-deprived participants will find a different answer than one measuring memory in well-rested young adults, even at the same dose.

One practical implication worth noting is that a short gap in creatine dosing matters less for brain function than for muscle performance. Once brain creatine levels rise, they remain elevated for weeks to months after stopping supplementation, significantly longer than muscle creatine, which drops back to baseline within 4 to 6 weeks.

Regional Brain Differences

Brain creatine does not increase equally across all regions after supplementation. The regions that respond most are those with the highest baseline energy demand — the frontal cortex and thalamus draw heavily on the creatine buffer during normal function and show the greatest increases when that buffer is expanded. The hippocampus and grey matter respond less. This is consistent with what the Dechent data showed: thalamus at 14.6 percent, white matter at 11.5 percent, cerebellum at 5.4 percent, grey matter at 4.7 percent.

Part of why this pattern went unrecognized for so long is a technical one. Early MRS studies used low-resolution methods that could not map regional differences with sufficient precision. The literature looked more consistent than it actually was because the tools were not sensitive enough to show the variation.

The CONCRET-MENOPA frontal brain creatine finding directly fits this pattern. The frontal cortex appears to be among the more responsive regions, which is consistent with the executive function and reaction time improvements that the trial measured.

Why This Gap Matters

The cognitive research on creatine has used doses of 3 to 8 grams per day. The brain creatine increases at those doses are 5 to 15%, not the near-complete saturation achievable in muscle. The BBB transporter becomes saturated before the brain reaches that point. This is the structural reason why pharmaceutical companies keep inventing new compounds: the ceiling on oral delivery is real, and getting around it requires either a different molecule or a different delivery route.

The Bottom Line

Oral creatine monohydrate is not ineffective for the brain. It meaningfully raises brain creatine, and that increase matters under the right conditions. But the ceiling is structural, not a dosing failure. And the brain’s own production system, while remarkable, cannot fully close the gap on its own.

The question this article raises — how do you actually get more creatine into the brain, and what happens when you do — is what the next article answers.

This is just the beginning of the Creatine Brain Series.

We have already covered:

What Creatine Actually Does to Your Brain — Importance of creatine to your brain health

Creatine for the Healthy Brain: Dose, Timing and Real Effects — The specific protocols to supplement creatine, and who could be deficient and what you should do

Your Steak Is Lying to You: The Creatine Content Reality — How much creatine do you get from cooked food

Your Creatine Baseline Exists. Medicine Just Cannot Measure It Yet — Methods to measure your creatine baseline

Not All Creatine Is the Same — The honest science-based breakdown of every creatine form on the market

What I will talk about as we go through this series into a booklet is:

• Why the cheapest supplement barely reaches your brain — and the emerging compounds that might actually fix that

• GAA: the creatine precursor that crosses the blood-brain barrier differently

• Who responds most to brain-targeted creatine — and why your biology determines the answer

• Creatine in disease, recovery, aging, and high-performance states

Fuel my day? ☕️🚀😊

Walk into any supplement store or open any health retailer online, and the creatine aisle will do its best to confuse you. Creatine monohydrate. Creatine HCl. Buffered creatine. Creatine ethyl ester. Creatine nitrate. Creatyl-L-leucine. Each one comes with marketing language that promises superior absorption, faster uptake, less bloating, and better results.

That is the short version. The long version is more interesting because the question of how to get creatine into your brain specifically is not the same question as how to get it into your muscles.

This article covers one question: which form of creatine should you actually buy, and why does the rest of the aisle exist if none of it outperforms the cheapest option? The answer is in the evidence, and the evidence is not complicated.

Read more

When I first started researching this piece, I assumed there was a standard test that could give us our muscle creatine level. A simple blood panel. Something a doctor could order on a Tuesday afternoon.

Oh boy, was I wrong.

After working through several peer-reviewed papers, looking at clinical trial methodology, and a conversation with a physician friend who confirmed my suspicion that this is not as straightforward as the supplement industry implies, here is what I actually found.

The Creatine test confusion

Before we talk about a personal creatine baseline, there is some confusion worth clearing up first. It trips up almost everyone who starts supplementing and then gets a blood panel back. A lot of people see “creatinine” on their lab report and mistake it for “creatine.” They assume the doctor is directly measuring their muscle fuel or tracking some kind of creatine ratio. But the kidneys don’t actually deal with creatine itself. They deal with creatinine, which is the waste product left behind after your muscles burn that fuel. It circulates in your blood until it is filtered out by your kidneys.

Think of it like a car. Creatine is the fuel sitting in the tank, ready to power the engine. Creatinine is the exhaust left behind after that fuel has been burned. Measuring the exhaust tells you some information about how the system is running; it does not tell you how much fuel is actually in the tank. This confusion comes down to a simple naming issue, but mixing up the asset with the waste product completely distorts what the blood test is actually looking at. Next time your doctor orders a kidney function test, the number that comes back will be your serum creatinine level, not the creatine stored in your muscles.

Creatinine

Skeletal muscles continuously release creatinine into the bloodstream as they burn creatine for energy. That means the amount of waste the body produces depends mostly on how much muscle you have and how active you are, not on how well your kidneys work. Someone who is physically active and carries significant muscle mass has larger creatine stores, so they naturally produce more creatinine waste every single day, even with perfect kidneys. Their baseline creatinine is just higher, and that is completely normal physiology, not a sign of kidney trouble. Checking a single blood test and assuming it means kidney damage completely ignores basic biology and gives you a false reading.

Age complicates the picture further due to two major factors.

1. Muscle mass generally declines with age.

2. Kidney filtration gradually decreases with age.

Those two changes can pull serum creatinine in opposite directions, which is part of why this number is less straightforward than people assume.

This is exactly why clinicians do not stop at creatinine alone. They calculate eGFR, the estimated Glomerular Filtration Rate, which factors in age and sex alongside the creatinine level to provide a much better estimate of actual kidney function, although, like any estimate, it has limitations. And if a result still looks ambiguous after that, there are more specific follow-up tests. Cystatin C is one example, a protein produced by the body at a steady rate that is not affected by muscle mass, which can help clarify whether an elevated reading reflects muscle mass, diet, supplementation, or an actual kidney concern.

What this means if you are taking creatine

If you start supplementing, your next blood panel will show a mildly elevated serum creatinine level. This is a known and well-documented finding in healthy people. Creatine supplementation can produce a small increase in serum creatinine because more creatine is available inside the body to undergo its normal, ongoing conversion into creatinine. On its own, in someone with normal kidney function, this is not evidence of kidney damage. It is exactly what biology predicts.

This is one of the most common sources of unwarranted alarm in creatine literature, and it is worth knowing before you ever see the number, not after you have already panicked at a routine physical. If a reading does come back elevated, the right response is not to assume the worst.

So, How Do You Actually Measure Your Creatine Baseline?

The short answer is: not easily, and probably not at your next GP appointment.

Here is what exists at each level, from what is available today to what is coming.

What a standard blood panel gives you

A routine metabolic panel measures serum creatinine and calculates your eGFR from it. As we covered earlier, this only tells your doctor how well your kidneys filter out waste. It cannot tell you how much creatine is actually stored inside your muscles. These are entirely different numbers measuring entirely different things, and confusing them is the most common mistake people make when reading their own lab results.

If the gold-standard muscle biopsy tests are locked away in research labs, what about other blood markers?

That is where plasma creatine comes in. This is a real medical measurement, and it is completely distinct from creatinine.

Plasma creatine reflects the amount of creatine circulating in the blood at a given moment, before it is taken up by tissues and undergoes normal metabolic turnover. In one of the largest population studies to measure this directly, the PREVEND study, mean plasma creatine concentrations were around 42 µmol/L in women and 29 µmol/L in men, with substantial individual variation around both averages. The exact values can vary depending on the laboratory, analytical methods, diet, and individual factors, so no single number can be applied universally. What is consistent across all the creatine studies is the sex difference: women generally have higher plasma creatine concentrations than men, likely because lower average muscle mass means less creatine is being taken up into storage, leaving more in circulation at any given time.

The problem? Plasma creatine is not included on standard blood panels, and most clinicians never routinely order it. More importantly, medicine has no established clinical threshold to tell you what your number actually means. There is no validated “low” cut-off that proves you need to supplement, the way there is for Vitamin D or ferritin. Even if you convince your doctor to order the test, there is little evidence-based guidance on how to interpret the result for otherwise healthy people considering creatine supplementation.

This highlights a confusing twist. A higher plasma creatine level does not always indicate higher muscle stores. In fact, in some situations, a higher number may reflect lower muscle uptake or lower muscle mass rather than larger creatine stores. Because plasma creatine is influenced by so many variables, blood levels simply are not reliable predictors of how much creatine is actually stored inside the muscle.

Think about it like a storage tank. Imagine two people—one highly muscular, one with very little muscle—and both take a 5-gram scoop of creatine powder.

The muscular individual has a much bigger reservoir capable of taking up that creatine over the next several hours, so their plasma creatine levels tend to fall more quickly after supplementation.

At the same time, because the person with less muscle has a lower total storage capacity, a greater proportion of that absorbed creatine remains in circulation, causing a larger temporary spike in their blood before it is eventually filtered by the kidneys and excreted in their urine.

Over time, some of the body’s total creatine pool naturally converts to creatinine every single day. Because supplementing increases the total amount of creatine available in the body, serum creatinine waste can rise slightly in some people, even when their kidney function is completely normal.

Ultimately, the relationship between what is floating in your bloodstream and what is locked inside your muscles is not straightforward; it is complex and often counterintuitive. The number exists. What it means for you personally is difficult to say.

What most people actually do

In the absence of a practical clinical test, what almost everyone does is estimate their likely position in the population range based on the factors that shift it. Sex. Age. Total muscle mass. Dietary pattern.

A 65-year-old vegetarian woman is almost certainly sitting near the lower end of the range, likely 100 to 110 mmol per kg, possibly lower.

A 30-year-old male omnivore who resistance trains three times a week is probably near the middle to upper end, 125 to 135 mmol per kg or above.

Neither of them has a precise number. But for the practical question of whether supplementation is likely to produce a meaningful response, the estimate is usually sufficient. The people most likely to benefit are also, in most cases, the easiest to identify without a test.

The math is imprecise. But the direction it points is reliable. So let’s do some math.

The total creatine pool, comprising free creatine and phosphocreatine, is about 120 to 130 mmol per kilogram of dry muscle mass in an individual consuming a diet containing meat and seafood. The range across the general population runs from approximately 100 mmol/kg at the lower end to about 140 mmol/kg at the upper end.

To translate that into grams of total body creatine, the calculation is straightforward but requires two numbers: your muscle creatine concentration in mmol/kg dry mass, and your total skeletal muscle mass in kilograms.

Now, let’s look at the math using a 150-pound (68 kg) person who carries roughly 64 pounds (29 kg) of wet skeletal muscle.

To determine the actual creatine storage, we first need to apply a wet-to-dry conversion, since muscle tissue is roughly 75% water. That means our 64 pounds (29 kg) of wet muscle is actually about 16 pounds (7.25 kg) of dry mass.

That is where the commonly cited “120 grams of total body creatine” figure actually comes from. It does not represent the whole body — it is only the muscle fraction. It also completely assumes average muscle mass, average concentration, and a standard diet. Change any of those three inputs, and that number shifts instantly.

How gender changes the calculation

The tissue concentration is essentially the same between men and women, both averaging around 120 mmol/kg dry muscle mass. The divergence is in the total pool and is driven entirely by differences in total muscle mass.

For example, let’s take a typical young adult man who carries roughly 35 to 40 kilograms of skeletal muscle. A typical young adult woman will carry roughly 23 to 28 kilograms. Running the same calculation:

Same concentration per kilogram of tissue. About 35 to 40 percent less total creatine in the pool, purely because of the difference in how much muscle is present.

There is a secondary factor that does not show up in the biopsy numbers but is clinically relevant: median plasma creatine concentrations are higher in females than in males, at 41 micromol/L versus 28 micromol/L. Women circulate more creatine in their blood relative to men, possibly because lower muscle mass means less uptake of circulating creatine into storage, leaving more in circulation. This is not a sign of higher reserves. It may actually reflect the opposite, less muscle available to absorb what is circulating.

Hormonal fluctuations during the menstrual cycle, pregnancy, and menopause add further variability in women, and the standard baseline numbers will not capture this. This makes women a particularly responsive group to supplementation, but the gender influence on creatine levels remains an understudied area in the existing literature.

How age changes the calculation

Older adults tend to have lower creatine levels in their outer thigh muscles. This decline happens mostly because aging triggers a loss of fast-twitch muscle fibres that store the most creatine. Changes in diet and physical activity could also contribute to these changes.

Type II muscle fibres are the fast-twitch fibres, and they hold significantly more creatine per kilogram than slow-twitch Type I fibres. As we lose these fast-twitch fibres to age-related muscle wasting (sarcopenia), the average creatine concentration in older muscles drops. Biopsy data and supplementation studies in aging adults suggest that baseline muscle creatine in adults over 65 tends toward the lower end of the normal range, likely between 100 and 110 mmol/kg, driven primarily by the preferential loss of fast-twitch muscle fibres, which store the most creatine per kilogram of tissue.

The combined effect of lower concentration and reduced total muscle mass compounds with age:

When an older adult or a woman takes the exact same dose, that powder enters a completely different environment. First, they have less overall muscle mass, meaning their absolute storage capacity—the physical size of the tank—is smaller. Second, due to age-related fibre loss or hormonal differences, the muscle they do have is running on fumes, sitting right at the bottom of the normal concentration range. Because they have both a smaller tank and a lower fuel level, supplementation hits them like a tidal wave. That is the biological reason why women and older adults experience the largest, most dramatic performance spikes in research. It isn’t some medical anomaly. It is just basic math.

This double whammy of a smaller muscle tank and a lower baseline fuel level is exactly why a standard one-size-fits-all dosing guide doesn’t make sense. Because their total storage capacity is smaller, an older adult or a smaller woman might easily max out their muscle stores on a lower daily dose—say, just 3 grams a day. Meanwhile, a muscular, young guy with double the muscle mass might need a full 5 grams a day just to keep his larger tank saturated. While those specific numbers are completely hypothetical, the underlying logic is non-negotiable: your ideal daily dose ultimately depends on how much muscle you are trying to fuel.

Anything you take beyond that personal ceiling can’t be stored; it just spills into your blood, hits your kidneys, and becomes expensive urine.

The gold standard that is not available to you

The gold standard is a needle biopsy of the vastus lateralis — dried, analyzed in a laboratory, and reported in millimoles per kilogram of dry mass.

This is how every number in the preceding sections was originally established. It is accurate, specific, and not something your doctor will order for you. It is a research procedure used in specific clinical trials and elite sports medicine settings. It requires specialist equipment and interpretation and carries a small procedural risk. For research purposes, it stays irreplaceable. For routine clinical use, it does not exist.

The most promising method that is not quite here yet

The D3-creatine dilution method is worth knowing about because it is the most likely bridge between high-tech lab research and your local doctor’s office.

The method is beautifully simple. You swallow a small, harmless dose of tagged creatine — specifically, creatine that has been labelled with a safe, stable isotope called deuterium-d3, making it chemically identical to normal creatine but traceable in the body. Because your muscles are your body’s main creatine storage tank, they absorb this tagged fuel and naturally turn it into tagged waste creatinine.

A few days later, you give a urine sample. Researchers look at how much that tagged waste was diluted by the normal, untagged waste already in your system. By looking at that dilution ratio, they can mathematically calculate your exact total muscle mass, and by that, the creatine storage capacity and baseline. No needles, no giant scanning beds, and no strict dieting required.

This method is completely non-invasive, highly accurate, and has actually been shown to beat standard DXA body-fat scans for measuring real muscle tissue. Right now, scientists are using it in major Canadian clinical trials to track age-related muscle loss over time.

You can’t walk into your regular doctor’s office and request it today. But as muscle wasting becomes a massive healthcare priority, this is the exact technology that will likely make tracking your personal creatine baseline accessible in the next decade.

What Your Doctor Can Actually Tell You

You cannot walk into a clinic and ask for your muscle creatine concentration. But there are two things a standard panel can tell you that are relevant:

Serum creatinine, interpreted alongside your eGFR, tells you whether your kidneys are clearing the waste product of creatine turnover normally. If your eGFR is normal and your creatinine is slightly elevated, and you have substantial muscle mass or are supplementing, that is expected physiology, not a red flag.

Higher estimated intramuscular creatine concentrations were associated with lower all-cause mortality in females, with a weaker trend in males. This is a recent finding from a large population study, and it is worth noting because it suggests that intramuscular creatine may have health relevance beyond athletic performance. But the method used to estimate intramuscular creatine in that study was not a biopsy — it was calculated from plasma creatine and the transcellular gradient. This approach is still in research territory and is not something your doctor will offer you as a standard test.

The practical reality is this: your personal muscle creatine baseline is a number you will almost certainly never know precisely. What you can know is where you probably sit relative to the population range, based on your sex, age, diet, and muscle mass — and therefore how much room you likely have before supplementation runs out of road.

The Brain: A Different Story

Everything above has a clean answer because muscle creatine has been measured the same way, by biopsy, for decades. The brain does not have that luxury yet, and it is worth being honest about why.

Your muscles get creatine almost entirely from diet, your own synthesis, or supplementation, all feeding into one measurable pool. The brain does not work quite the same way. Creatine can cross the blood-brain barrier through a dedicated transporter, but neurons can also make their own creatine locally. That means brain creatine is a mix of what arrives from circulation and what gets manufactured on site, and right now there is no agreed method for separating the two or defining what a healthy total should be.

This is why you will not find a brain equivalent of 150 to 160 mmol per kg dry mass. That number exists for muscle because Hultman and Greenhaff measured it directly, in biopsied tissue, in the 1990s. Nobody has produced that number for the brain, because nobody can biopsy a living brain the way you can biopsy a thigh muscle.

What researchers can do is scan the brain using magnetic resonance spectroscopy and watch creatine levels change with supplementation. And what those scans show is genuinely encouraging, if still early. In a small Alzheimer’s trial, brain creatine rose in 85 percent of participants after eight weeks of supplementation by an average of 11 percent. In healthy adults given a single large dose before a night of sleep deprivation, brain creatine rose within hours, and cognitive performance held up better than in those given a placebo.

But the dosing picture is still inconsistent in a way that matters. One randomized controlled study gave healthy young adults either 10 or 20 grams of creatine per day for six weeks. Despite those doses being higher than what several earlier studies used to show cognitive benefits, brain creatine did not increase significantly. The researchers concluded that higher doses, longer duration, or both may be needed to reliably elevate brain creatine in healthy people with normal baseline levels.

The honest summary

Supplementation does raise brain creatine. That much is established. Low starting levels do appear to predict a bigger response (or a higher creatine uptake), the same pattern seen in muscle. But there is no confirmed number that tells you your brain has enough, no agreed ceiling, and no settled answer for how much, or for how long, you would need to supplement to reach whatever that number turns out to be.

Anyone who tells you otherwise is filling a gap that the research has not yet filled.

This is just the beginning of the Creatine Brain Series.

We’ve already covered:

What Creatine Actually Does to Your Brain - Importance of creatine to your brain health

Creatine for the Healthy Brain: Dose, Timing & Real Effects - The specific protocols to supplement creatine, and who could be deficient and what you should do.

Your Steak Is Lying to You: The Creatine Content Reality - How much creatine do you get from cooked food

I am pulling together the clearest, most practical roadmap available — combining the latest research with real-world application so you can actually use this information.

If you want the full picture, the practical protocols, the individual breakdowns, and the updates as new studies drop, the rest of the series is where it all comes together.

Stay tuned — the next installment is dropping soon. This is one of the most actionable areas in brain health research right now, and the field is moving fast.

Fuel my day? ☕️🚀😊

References

1. Harris RC, Lowe JA, Warnes K, Orme CE. The concentration of creatine in meat, offal and commercial dog food. Research in Veterinary Science. 1997;62(1):58-62.

2. Purchas RW, Busboom JR. The effect of production system and age on levels of iron, taurine, carnosine, coenzyme Q10, and creatine in beef muscles and liver. Meat Science. 2004;70(3):589-596.

3. Brosnan ME, Brosnan JT. The role of dietary creatine. Amino Acids. 2016;48(8):1785-1791.

4. Korovljev D, Todorovic N, Stajer V, Ostojic SM. Temporal trends in dietary creatine intake from 1999 to 2018: an ecological study with 89,161 participants. Journal of the International Society of Sports Nutrition. 2021;18(1):55.

5. Kreider RB, Stout JR. Creatine in Health and Disease. Nutrients. 2021;13(2):447.

6. Hultman E, Söderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine loading in men. Journal of Applied Physiology. 1996;81(1):232-237.

7. Greenhaff PL, Bodin K, Söderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. American Journal of Physiology. 1994;266(5 Pt 1):E725-730.

8. Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proceedings of the Royal Society B: Biological Sciences. 2003;270(1529):2147-2150.

9. Benton D, Donohoe R. The influence of creatine supplementation on the cognitive functioning of vegetarians and omnivores. British Journal of Nutrition. 2011;105(7):1100-1105.

10. McMorris T, Mielcarz G, Harris RC, Swain JP, Howard A. Creatine supplementation and cognitive performance in elderly individuals. Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition. 2007;14(5):517-528.

11. Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D. Effects of creatine supplementation on cognitive function of healthy individuals: a systematic review of randomized controlled trials. Experimental Gerontology. 2018;108:166-173.

12. Prokopidis K, Giannos P, Triantafyllidis KK, Kechagias KS, Forbes SC, Candow DG. Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews. 2023;81(4):416-427.

13. Xu C, Bi S, Li Z, Wang Y, Zhou Y. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Frontiers in Nutrition. 2024;11:1424972.

14. Candow DG, Forbes SC, Chilibeck PD, et al. Creatine O’Clock: Does Timing of Ingestion Really Influence Muscle Mass and Performance? Frontiers in Sports and Active Living. 2022;4:869071.

15. Roitman S, Green T, Osher Y, Karni N, Levine J. Creatine monohydrate in resistant depression: a preliminary study. Bipolar Disorders. 2007;9(7):754-758.

16. Juneja M, Bhatt K, Bhatt D. Creatine Supplementation in Depression: A Review of Mechanisms, Efficacy, Clinical Outcomes, and Future Directions. Cureus. 2024;16(3):e56117.

17. Kreider RB, Jäger R, Purpura M. Bioavailability, Efficacy, Safety, and Regulatory Status of Creatine and Related Compounds: A Critical Review. Nutrients. 2022;14(5):1035.

18. Jäger R, Purpura M, Shao A, Inoue T, Kreider RB. Analysis of the efficacy, safety, and regulatory status of novel forms of creatine. Amino Acids. 2011;40(5):1369-1383.

19. Buford TW, Kreider RB, Stout JR, et al. International Society of Sports Nutrition position stand: creatine supplementation and exercise. Journal of the International Society of Sports Nutrition. 2007;4:6.

20. Smith MA, Taylor MK, Bhatt D, et al. Creatine monohydrate pilot in Alzheimer’s: Feasibility, brain creatine, and cognition. Alzheimer’s and Dementia: Translational Research and Clinical Interventions. 2025. PMC12089086.

21. Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. American Journal of Physiology. 1999;277(3):R698-704.

22. Gibbons TD, Stuckless TJR, Bhatt D, et al. Dose-Response of Creatine Supplementation on Cognitive Function in Healthy Young Adults. Nutrients. 2023;15(18):4027.

23. Bakker SJL, van den Berg EH, Navis GJ, et al. Plasma creatine, estimated intramuscular creatine, transcellular gradient and the risk of mortality: Results from the PREVEND study. Journal of Cachexia, Sarcopenia and Muscle. 2025.

24. Connelly MA, van den Berg EH, Bakker SJL, et al. Plasma creatine concentration is associated with incident hypertension in the PREVEND study. Journal of Hypertension. 2022;40(2):271-278.

25. van den Berg EH, Flores-Guerrero JL, Gruppen EG, et al. Plasma creatine and incident type 2 diabetes in a general population-based cohort: The PREVEND study. Clinical Endocrinology. 2021;94(3):450-458.

26. Cooke MB, Brabham B, Buford TW, et al. Muscular Atrophy and Sarcopenia in the Elderly: Is There a Role for Creatine Supplementation? Biomolecules. 2019;9(11):642.

27. Candow DG, Forbes SC, Chilibeck PD, et al. Variables Influencing the Effectiveness of Creatine Supplementation as a Therapeutic Intervention for Sarcopenia. Frontiers in Nutrition. 2019;6:124.

28. Burke DG, Chilibeck PD, Parise G, Candow DG, Mahoney D, Tarnopolsky M. Effect of creatine and weight training on muscle creatine and performance in vegetarians. Medicine and Science in Sports and Exercise. 2003;35(11):1946-1955.

29. Kaviani M, Shaw K, Chilibeck PD. Benefits of Creatine Supplementation for Vegetarians Compared to Omnivorous Athletes: A Systematic Review. International Journal of Environmental Research and Public Health. 2020;17(9):3041.

30. Marshall RN, Smeuninx B, Morgan PT, Breen L. Creatine and Cognition in Aging: A Systematic Review of Evidence in Older Adults. Nutrients. 2025.

The last article ended with a promise. Before you ever open a supplement tub, it is worth knowing where you actually stand.

That depends on more than diet alone. Your age, lifestyle, underlying health conditions, sleep, and a handful of other factors all shape your starting point. But food is where the biggest differences live, and it is the piece almost nobody talks about honestly.

Most creatine content skips this conversation entirely. It assumes you are already supplementing and jumps straight to dosing. That is part of why creatine got boxed into a fitness product. People who do not lift weights tuned out, and some tuned in just long enough to decide the whole culture was not for them. The biology never got a fair hearing.

Here is the reality and what the biology actually says. We all need creatine. Our brains and muscles depend on it. it. But the starting line is not the same for everyone. An omnivore eating red meat three times a week and a vegan eating no animal products at all are not just at different points on the same line. They are operating from fundamentally different baselines, and that changes what supplementation does, how much you need, and how strongly you are likely to respond.

This article does the calculation honestly, group by group.

In this article:

• Why natural food sources and supplements are not interchangeable — and the reality of how much creatine actually reaches your body

• Why a pan-fried salmon fillet and a measured scoop of powder are not interchangeable, even if the numbers on paper look similar

• The specific cooking methods that preserve the most creatine versus the ones that quietly destroy it

• The real gap between what a typical omnivore diet delivers and what the cognitive trials actually used — and why that gap is bigger than almost anyone realizes

And in the next article:

• A full breakdown of every major food group and exactly how much creatine each one contains — meat, fish, dairy, eggs, and yes, plant foods too, with honest numbers for each and how much creatine you get to use inside the body

• Why the cheapest creatine on the market outperforms products costing three times as much, and what to actually look for on a label

• Which diet type starts furthest behind before they ever open a supplement tub — and which group has the strongest science for supplementation

Why food-based creatine is more complicated than it looks

Creatine occurs naturally in animal muscle tissue. The richest sources are the ones you would expect — red meat, pork, fish. But the amount of creatine you absorb from food is not the same as the amount sitting in the raw ingredient, and that gap matters more than most people realize.

What Your Pan Is Actually Doing to Your Creatine

Heat is the first problem, and it is worth understanding exactly what heat does rather than just knowing it causes loss.

Creatine is heat-sensitive. How much survives cooking depends on two variables: temperature and time.

Read more